HIV-1 fitness and antiretroviral drug resistance

AIDS Reviews

Volumn 3, Issue 4, 2001, Pages 223-242

  Quiñones Mateu, Miguel E ^a   Weber, Jan ^a   Rangel, Hector R ^a   Chakraborty, Bikram ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Drug resistance; Evolution; Fitness; Genetic variability; HIV

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); ABACAVIR; ABT 77003; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; FOSCARNET; INDINAVIR; LAMIVUDINE; LOPINAVIR; MOZENAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; QYL 609; QYL 685; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; RTI 85127; SAQUINAVIR; STAVUDINE; T 1249; TENOFOVIR; TL 3; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ASSAY; BIOLOGICAL MODEL; CLINICAL TRIAL; COMPARATIVE STUDY; CROSS RESISTANCE; DISEASE COURSE; DRUG EFFICACY; DRUG SCREENING; DRUG SPECIFICITY; EVOLUTION; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; POPULATION SIZE; REVIEW; VIRAL GENETICS; VIROGENESIS; VIRUS GENOME; VIRUS ISOLATION; VIRUS LOAD; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 0035735558     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (166)

1. RNA virus mutations and fitness for survival
2. The red queen reigns in the kingdom of RNA viruses
3. Exponential increases of RNA virus fitness during large population transmissions
4. Fitness of RNA virus decreased by Muller's ratchet
5. Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events
6. Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants
7. Quantitation of relative fitness and great adaptability of clonal populations of RNA viruses
8. Rates of spontaneous mutation among RNA viruses
9. Mutation rates and rapid evolution of RNA viruses
10. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase
11. Viral quasispecies
12. High error rates, population equilibrium, and evolution of RNA replication systems
13. Viral quasispecies and fitness variations
14. Basic concepts in RNA virus evolution
15. Evolution in Mendelian populations
16. Rapid selection in modified BHK-21 cells of a foot-and-mouth disease virus variant showing alterations in cell tropism
17. The red queen reigns in the kingdom of RNA viruses
18. Exponential increases of RNA virus fitness during large population transmissions
19. RNA virus quasispecies: Significance for viral disease and epidemiology
20. Replicative capacity, cytopathic effect and cell tropism of HIV
21. HIV drug resistance and viral fitness
22. Implications of antiretroviral resistance on viral fitness
23. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme
24. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy
25. Human immunodeficiency virus fitness in vivo: Calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase
26. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215
27. Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations
28. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors
29. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors
30. Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation
31. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
32. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1
33. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo
34. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi- dideoxynucleoside resistance
35. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
36. Relative replication fitness of a high-level 3′-azido-3′-deoxythymidine- resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-
37. A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression
38. The effects of dNTP pool imbalances on frameshift fidelity during DNA replication
39. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus
40. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy
41. Comparison of selective polymerase chain reaction primers and differential probe hybridization of polymerase chain reaction products for determination of relative amounts of codon 215 mutant and wild-type HIV-1 populations
42. Nevirapine-resistant human immunodeficiency virus: Kinetics of replication and estimated prevalence in untreated patients
43. Resistance of human immunodeficiency virus type 1 to protease inhibitors: Selection of resistance mutations in the presence and absence of the drug
44. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients
45. Amprenavir resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity
46. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
47. Natural variation of replication capacity measurements in drug-naive/susceptible HIV-1
48. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus
49. Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy
50. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro
51. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants
52. Patterns of changes in human immunodeficiency virus type 1 V3 sequence populations late in infection
53. A novel recombinant marker virus assay for comparing the relative fitness of HIV-1 reverse transcriptase variants
54. A bacteriophage lambda-based genetic screen for characterization of the activity and phenotype of the human immunodeficiency virus type 1 protease
55. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: Virus fitness in the absence and in the presence of drug
56. A multiple-site-specific heteroduplex tracking assay as a tool for the study of viral population dynamics
57. Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure
58. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay
59. Analyses of in vitro and in vivo intersubtype HIV-env recombination
60. Recombinant virus assay: A rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates
61. A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors
62. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
63. HIV type 1 protease cleavage site mutations and viral fitness: Implications for drug susceptibility phenotyping assays
64. Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: A comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val
65. In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection
66. Large fitness differences between protease inhibitor susceptible and resistant HIV-1 in vivo
67. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management. International AIDS Society-USA Panel
68. International perspectives on antiretroviral resistance. Resistance to protease inhibitors
69. International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance
70. International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance
71. Pol gene quasispecies of human immunodeficiency virus: Mutations associated with drug resistance in virus from patients undergoing no drug therapy
72. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: Presence of protease inhibitor-resistant variants in untreated subjects
73. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
74. Prediction of progression to AIDS with serum HIV-1 RNA and CD4 count
75. Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants
76. HIV-1 evolution under pressure of protease inhibitors: Climbing the stairs of viral fitness
77. Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles
78. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites
79. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors
80. Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy
81. Contribution of accumulated Gag and protease mutations towards the recovery of the fitness and the virus particle formation in the protease inhibitor-resistant HIV-1 with D30N and L90M
82. Evolution of phenotypic drug susceptibility and viral replication capacity during stable protease inhibitor-based therapy despite incomplete viral suppression
83. A pilot study to analyze HIV-1 fitness evolution under a protease inhibitor-based therapy shows a diverse response depending of the basal genotypic context of the virus
84. Mutations in the protease gene of human immunodeficiency virus type 1 affect release and stability of virus particles
85. A guide to HIV-1 reverse transcriptase and protease sequencing for drug resistance studies
86. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays
87. Limited sequence diversity of the HIV type 1 protease gene from clinical isolates and in vitro susceptibility to HIV protease inhibitors
88. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: Amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1
89. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor
90. Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy
91. Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity
92. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
93. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
94. Novel Gag-Pol frameshift site in human immunodeficiency virus type 1 variants resistant to protease inhibitors
95. Population dynamics studies of wild-type and drug-resistant mutant HIV in mixed infections
96. Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs
97. Point mutant frequencies in the pol gene of human immunodeficiency virus type 1 are two- to threefold lower than those of env
98. Functional correlates of insertion mutations in the protease gene of human immunodeficiency virus type 1 isolates from patients
99. HIV-1 with an insertion in protease is drug-susceptible, replication-competent and transmissible
100. Viral evolution in response to the broad-based retroviral protease inhibitor TL-3
101. Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription
102. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants
103. Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1
104. Evolution of AZT resistance in HIV-1: The 41-70 intermediate that is not observed in vivo has a replication defect
105. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication
106. Role of methionine 184 of human immunodeficiency virus type-1 reverse transcriptase in the polymerase function and fidelity of DNA synthesis
107. Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase
108. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
109. Reverse transcriptase fidelity and HIV-1 variation
110. Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: The relative roles of drift and selection
111. Impaired fitness of foscarnet-resistant strains of human immunodeficiency virus type 1
112. In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues
113. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors
114. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5′-end- and DNA 3′-end-directed RNase H activities
115. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture
116. A mutation in reverse transcriptase of bis(heteroaryl)piperazine- resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors
117. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)
118. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants
119. In vitro analysis of HIV-1 resistance to nevirapine and fitness determination of resistant variants
120. Role of human immunodeficiency virus type 1 group O in the AIDS pandemic
121. Two unrelated studies from 1 lab: HIV drug resistance in the US and decay of latency
122. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group
123. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
124. Persistence of multidrug resistant HIV-1 with diminished fitness acquired in primary infection
125. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance
126. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides
127. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel
128. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors
129. Dynamics of dominance of a dipeptide insertion in reverse transcriptase of HIV-1 from patients subjected to prolonged therapy
130. Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance
131. Decreased viral fitness conferred by a multidrug-resistant HIV-1 reverse transcriptase harbouring a dipeptide insertion between codons 69 and 70
132. Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs
133. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults
134. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV- suppressive factors produced by CD8+ T cells
135. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist
136. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
137. HIV resistance to entry inhibitors
138. Analysis of the temporal relationship between human immunodeficiency virus type 1 quasispecies in sequential blood samples and various organs obtained at autopsy
139. Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs
140. Reduced fitness of HIV-1 that are resistant to CXCR4 antagonists due to alterations in gp120 function
141. The fusion inhibitors T-20 and T-1249 demonstrate potent in vitro antiviral activity against clade B HIV-1 isolates resistant to reverse transcriptase and protease inhibitors and non-B clades
142. Impaired fitness of HIV-1 site-directed mutants resistant to T-20
143. Evolution of resistance to integration inhibitors: The selection of integrase active site mutations results in multiple affects on viral replication that are partially restored by truncating Vpu
144. Determinants of virological response to antiretroviral therapy: Implications for long-term strategies
145. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
146. Proposed alternatives for the use of anti-HIV drugs
147. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor- sensitive genotype
148. Substantial correlation between HIV type 1 drug-associated resistance mutations in plasma and peripheral blood mononuclear cells in treatment-experienced patients
149. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy
150. Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy
151. Selection of the M184V mutation during repetitive cycles of structured antiretroviral treatment interruptions
152. Reservoirs for HIV-1: Mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy
153. Memory in viral quasispecies
154. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy
155. Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes
156. Human immunodeficiency virus type 1 reverse transcriptase: Role of Tyr115 in deoxynucleotide binding and misinsertion fidelity of DNA synthesis
157. Mutational anatomy of an HIV-1 protease variant conferring cross- resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity
158. Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants
159. Complete mutagenesis of the HIV-1 protease
160. Interaction between two distinct plaque-cloned human immunodeficiency viruses (HIVs): The possible existence of heterozygous virus
161. Human immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing
162. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor
163. Evidence of a mutually exclusive relationship between the HIV-1 protease inhibitor resistance mutations D30N and L90M
164. Second-site reversion of a human immunodeficiency virus type 1 reverse transcriptase mutant that restores enzyme function and replication capacity
165. Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere
166. Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer